Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)

Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Treatment Approaches For Amyotrophic Lateral Sclerosis (Als) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting both upper and lower motor [neurons](/entities/neurons). Treatment involves disease-modifying therapies, symptomatic management, and multidisciplinary care to maximize quality of life and survival. [@brown2017]

FDA-Approved Disease-Modifying Therapies

Riluzole

• Mechanism: Blocks glutamate excitotoxicity, reduces glutamate release
• Effect: Modest survival benefit (2-3 months)
• Dose: 50 mg twice daily
• Side Effects: Nausea, liver enzyme elevation

Edaravone (Relyvrio)

• Mechanism: Free radical scavenger, reduces oxidative stress
• Effect: Slows functional decline in selected patients
• Administration: IV infusion, 10 days per 28-day cycle
• Side Effects: Fatigue, gait disturbance, headache

Tofersen (Qalsody)

...

Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Treatment Approaches for Amyotrophic Lateral Sclerosis (ALS)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Treatment Approaches For Amyotrophic Lateral Sclerosis (Als) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting both upper and lower motor [neurons](/entities/neurons). Treatment involves disease-modifying therapies, symptomatic management, and multidisciplinary care to maximize quality of life and survival. [@brown2017]

FDA-Approved Disease-Modifying Therapies

Riluzole

• Mechanism: Blocks glutamate excitotoxicity, reduces glutamate release
• Effect: Modest survival benefit (2-3 months)
• Dose: 50 mg twice daily
• Side Effects: Nausea, liver enzyme elevation

Edaravone (Relyvrio)

• Mechanism: Free radical scavenger, reduces oxidative stress
• Effect: Slows functional decline in selected patients
• Administration: IV infusion, 10 days per 28-day cycle
• Side Effects: Fatigue, gait disturbance, headache

Tofersen (Qalsody)

• Mechanism: ASO targeting SOD1 gene mutations
• Effect: Reduces SOD1 protein, slows disease progression in SOD1-ALS
• Administration: Intrathecal injection
• Indication: Confirmed SOD1 mutation

Symptomatic Management

Muscle Symptoms

• Baclofen: Spasticity management
• Tizanidine: Muscle relaxant
• Quinine: Cramp management (limited use due to cardiac risks)

Respiratory Support

• Non-invasive ventilation (NIV): First-line for respiratory insufficiency
• Invasive ventilation: Tracheostomy for advanced disease
• Cough assist devices: Secretion clearance

Nutritional Support

• Gastrostomy (PEG): When oral intake is insufficient
• High-calorie supplements: Counteract weight loss

Salivation Management

• Glycopyrrolate: Reduces drooling
• Botulinum toxin injections: For severe sialorrhea
• Suction devices: For excess secretions

Investigational Therapies

Gene-Silencing Approaches

• ASOs for [C9orf72](/entities/c9orf72): In clinical trials
• AAV-delivered RNAi: Early-stage development

Neuroprotective Agents

• CNM-Au8: Gold nanocrystals for energy enhancement
• Masitinib: Tyrosine kinase inhibitor
• Nuedexta: Combination for pseudobulbar affect

Cell-Based Therapies

• Stem cell transplantation: Various approaches in trials
• Neurotrophic factor delivery: AAV-mediated

Multidisciplinary Care

Optimal ALS management requires: [@hardiman2017]

• Neurology: Primary care coordination
• Pulmonology: Respiratory management
• Gastroenterology: Nutritional support
• Physical/Occupational Therapy: Mobility aids, equipment
• Speech Therapy: Communication, swallowing
• Social Work: Support services
• Mental Health: Psychological support

Clinical Trials

Active areas of investigation include: [@fda]

• Novel ASO therapies targeting various gene mutations
• Combination therapies
• Biomarker development for patient selection
• Repurposed drugs with neuroprotective properties

Background

The study of Treatment Approaches For Amyotrophic Lateral Sclerosis (Als) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [ALS Therapeutics](/treatments/als-therapeutics)
• [ALS Genetic Variants](/diseases/amyotrophic-lateral-sclerosis)
• [ALS Biomarkers](/content/biomarkers)
• [Relyvrio](/therapeutics/relyvrio)
• [Tofersen](/therapeutics/tofersen)

External Links

• [ALS Association](https://www.als.org/)
• [ALS Therapy Development Institute](https://www.als.net/)
• [ClinicalTrials.gov ALS Trials](https://clinicaltrials.gov/ct2/results?cond=ALS)

Emerging Therapeutic Approaches

Antisense Oligonucleotide (ASO) Therapies

Beyond tofersen for SOD1 mutations, several ASO therapies are in development:

• BIIB078 (C9orf72-ASO): Targeting the hexanucleotide repeat expansion in C9orf72, the most common genetic cause of familial ALS [1]
• ATL001 (SOD1-ASO): Next-generation SOD1 targeting with improved delivery
• WVE-004 (C9orf72-ASO): Wave Life Sciences program showing promise in preclinical models

Gene Therapy Vectors

Adeno-associated virus (AAV) delivery systems are being explored for:

• AAVrh.10 serotype: Natural tropism for motor neurons
• AAV-PHP.B: Enhanced peripheral and CNS transduction
• Non-viral delivery: Lipid nanoparticles for improved safety

Small Molecule Drug Repurposing

Several existing drugs are being evaluated for neuroprotective effects:

• Amantadine: NMDA receptor antagonist, modest benefit in some patients
• Ceftriaxone: Antibiotic showing glutamate transporter upregulation in preclinical studies
• Minocycline: Anti-inflammatory effects, mixed clinical results
• Lithium: Neuroprotective properties, controversial efficacy data

Immunomodulatory Approaches

Given the role of neuroinflammation in ALS:

• Mesenchymal stem cells: Immunomodulatory and neuroprotective properties
• Monoclonal antibodies: Targeting misfolded SOD1 or TDP-43
• Microglial modulation: CX3CR1 antagonists and colony-stimulating factor 1 receptor (CSF1R) inhibitors

Mitochondrial and Metabolic Therapies

Targeting energy metabolism defects in ALS:

• CoQ10 (Ubiquinone): Electron transport chain support, mixed trial results
• Edaravone: Approved free radical scavenger
• Relyvrio (sodium phenylbutyrate/taurursodiol): Targets mitochondrial dysfunction

Biomarkers in ALS Clinical Trials

Therapeutic Monitoring Biomarkers

• Neurofilament light chain (NfL): Blood and CSF biomarker correlating with disease progression [2]
• Neurofilament heavy chain (pNfH): Prognostic marker in SOD1-ALS
• Creatine kinase (CK): Muscle involvement marker

Genetic Biomarkers

• SOD1 mutation status: Predicts response to tofersen
• C9orf72 repeat size: Correlates with disease severity
• ATXN2 intermediate expansions: Modifies ALS risk and progression

Emerging Biomarkers

• TDP-43 fragments: CSF markers of neuronal damage
• microRNAs: Potential diagnostic and prognostic markers
• Muscle MRI: Non-invasive assessment of disease burden

Patient Selection for Specific Therapies

Genetic Testing Recommendations

All patients with ALS should be offered genetic testing for:

• C9orf72 hexanucleotide repeat expansion: Most common (~40% familial, ~5-10% sporadic)
• SOD1 mutations: ~15-20% of familial ALS
• FUS mutations: ~5% of familial ALS
• TARDBP mutations: Rare but clinically relevant

Phenotype-Genotype Correlations

• SOD1 A4V: Aggressive phenotype, rapid progression
• SOD1 D90A: Slower progression, typically Scandinavian ancestry
• C9orf72: Earlier onset, cognitive/behavioral involvement common
• FUS: Younger onset, rapid progression

Quality of Life Interventions

Communication Aids

• Eye-tracking systems: For patients with severe paralysis
• Brain-computer interfaces (BCI): Experimental neural prosthetics
• Speech generating devices: Smartphone and tablet-based solutions

Assistive Devices

• Powered wheelchairs: With advanced positioning
• Robotic arms: For upper extremity function
• Home modifications: Environmental control systems

Psychological Support

• Cognitive behavioral therapy: For depression and anxiety
• Support groups: Peer connections through ALS Association chapters
• Family counseling: Caregiver support and burnout prevention

References

: Miller RG, et al. [Ril